August 2025 – Kinstellar, together with Addleshaw Goddard as lead counsel, has advised Phoenix Equity Partners Limited, a leading UK-based private equity investor, in connection with the acquisition by Phoenix of FutureMeds, a fast-growing clinical trial site network operating across Europe, including subsidiaries in Bulgaria and Ukraine.
The transaction marks a significant step in Phoenix’s investment in the healthcare and life sciences sector and supports FutureMeds’ ambition to accelerate access to clinical trials across Europe and beyond. FutureMeds is Europe’s first dedicated independent site management organisation (SMO), providing access to state-of-the-art clinical research infrastructure across multiple countries.
Kinstellar provided local legal support on all Bulgarian and Ukrainian aspects of the transaction, including legal due diligence and regulatory analysis, including advice on competition, anti-trust and tax queries. The firm’s multidisciplinary teams in Sofia and Kyiv worked closely with Addleshaw Goddard to ensure seamless cross-border execution.
The Kinstellar team in Bulgaria was led by Diana Dimova (Managing Partner) and Denitsa Kuzeva (Senior Associate) and included Atanas Mihaylov (Counsel), Simeon Vachev (Senior Associate), Debora Dineva (Senior Associate), Vanya Evtimova (Consultant) and Simona Damyanova (Junior Associate).
The Kinstellar team in Ukraine was led by Olena Kuchynska (Managing Partner) and included Natalia Kirichenko (Partner), Lyudmyla Dzhurylyuk (Managing Associate), Yulia Eismont (Counsel), Olena Stanishevska (Senior Associate), Tetiana Kolha (Senior Associate), Olena Tsygulska (Associate), Diana Malysh (Associate) and Danylo Kholodyan (Associate).